Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.
about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsEmerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies.Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assayPre-existing Antibody: Biotherapeutic Modality-Based Review.Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications.An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus MacaquesNew human single chain anti-idiotypic antibody against benzo[a]pyrene.Evading pre-existing anti-hinge antibody binding by hinge engineering.Preexisting Antibodies to an F(ab')2 Antibody Therapeutic and Novel Method for Immunogenicity Assessment.Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics.Molecular characterization of human anti-hinge antibodies derived from single cell cloning of normal human B cells.Quartz crystal microbalance as an assay to detect anti-drug antibodies for the immunogenicity assessment of therapeutic biologics.CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6+ cells in an experimental suction blister.Development and characterization of an anti-rituximab monoclonal antibody panel.Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor.The Challenge of the Pathogenesis of Parkinson's Disease: Is Autoimmunity the Culprit?Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
P2860
Q26738810-79450380-3D50-4F88-BCEF-F2638304E210Q26739084-FC3C635A-FB86-4A16-BC30-B092D8008333Q33745965-F2737BFA-D97D-46E7-B799-48877F1AE447Q36653888-BEA5EA02-9156-4D33-8043-898DD699562EQ38946563-04D7192C-DDB2-4369-B4B0-7D2F619019FFQ38979811-7E41D21C-F0E9-46B9-A9F4-53743B448CE3Q40748041-B34DE18A-F0DE-4006-B8AD-EFE9314FF4F3Q41539697-FCC9E8CA-2F91-4ACF-8DEF-21D3D8E34F69Q42027130-88A0090D-CBD8-4E2F-A2D4-86F05EA5B8CAQ42058488-A6F9DC4F-B7AE-4ECA-AD66-556279A53344Q47099672-0A954587-C68F-45F1-9116-797324A01534Q47297643-61B63EE1-4A59-4B20-90E5-94278005416AQ47449187-0A248EE9-5823-4D00-A4F9-98F2AA189583Q48125445-A5A817D7-1B5E-4002-9B01-02A41DCAE01FQ50140061-B749BB6F-4598-42CA-86FB-2AE23D0FE14FQ55259703-885EC2D3-EB92-4467-82AE-CCEC60B245AEQ57490878-A6CE4E72-063C-472C-8474-7BA0DA728D17Q59128091-350BB0F0-A0D4-4D82-8DE0-209221B11786
P2860
Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cross-reactive and pre-existin ...... treatment and immunogenicity.
@ast
Cross-reactive and pre-existin ...... treatment and immunogenicity.
@en
type
label
Cross-reactive and pre-existin ...... treatment and immunogenicity.
@ast
Cross-reactive and pre-existin ...... treatment and immunogenicity.
@en
prefLabel
Cross-reactive and pre-existin ...... treatment and immunogenicity.
@ast
Cross-reactive and pre-existin ...... treatment and immunogenicity.
@en
P2093
P2860
P921
P1476
Cross-reactive and pre-existin ...... treatment and immunogenicity.
@en
P2093
Gerrit-Jan Wolbink
Karin A van Schie
Theo Rispens
P2860
P304
P356
10.1080/19420862.2015.1048411
P577
2015-07-01T00:00:00Z